US Bancorp DE Sells 22,670 Shares of Gilead Sciences, Inc. $GILD

Key Points

• US Bancorp DE reduced its stake in Gilead Sciences by 2.6%, selling 22,670 shares and holding 854,552 shares worth approximately $94.7 million.
• Gilead Sciences reported a Q2 EPS of $2.01, surpassing analysts' expectations, and achieved revenue of $7.08 billion, which also exceeded forecasts.
• The company recently announced a quarterly dividend of $0.79 per share, resulting in an annualized dividend yield of 2.7% and a dividend payout ratio of 62.95%.

US Bancorp DE decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 854,552 shares of the biopharmaceutical company's stock after selling 22,670 shares during the period. US Bancorp DE owned about 0.07% of Gilead Sciences worth $94,745,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Southland Equity Partners LLC raised its position in Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company's stock worth $364,000 after acquiring an additional 92 shares during the period. Twelve Points Wealth Management LLC raised its position in Gilead Sciences by 1.5% in the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company's stock worth $721,000 after acquiring an additional 98 shares during the period. Argentarii LLC raised its position in shares of Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after purchasing an additional 99 shares during the period. Investment Research & Advisory Group Inc. raised its position in shares of Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 100 shares during the period. Finally, Lodestar Private Asset Management LLC raised its position in shares of Gilead Sciences by 3.6% in the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company's stock valued at $318,000 after purchasing an additional 100 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $116.74 on Friday. The company has a 50 day moving average of $114.57 and a 200 day moving average of $110.19. The stock has a market cap of $144.85 billion, a P/E ratio of 23.26, a P/E/G ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Analyst Ratings Changes

Several analysts have recently issued reports on GILD shares. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. Cantor Fitzgerald boosted their price target on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an "overweight" rating in a research report on Thursday. Finally, Citigroup boosted their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $118.08.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the sale, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares in the company, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.